Bimatoprost
  
Side effects 
	
		
Options: 
			
			Show MedDRA Preferred Terms
		
	
	
| Side effect | Data for drug | Placebo | Labels | 
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 
| Pruritus | very common |  |  |  | x | x | x | x | x | x | x | x | 
| Growth of eyelashes | very common, 5% - 53.6% |  |  |  | x | x | x | x | x | x | x | x | 
| Conjunctival hyperaemia | very common, 3.4% - 56.1% |  | x | x | x | x | x | x | x | x | x | x | 
| Eye pruritus | 3.3% - 17.6% |  | x | x |  |  |  |  |  |  | x | x | 
| Dry eye | 2.1% - 11.6% |  | x | x |  |  |  |  |  |  |  | x | 
| Burning sensation in eye | 6.6% - 10.4% |  |  |  |  |  |  |  |  |  |  | x | 
| Blepharal pigmentation | 0.4% - 11.4% |  |  |  |  |  |  |  |  |  |  | x | 
| Headache | common |  |  | x | x | x | x | x | x | x | x | x | 
| Photophobia | common, 0.4% - 6.8% |  |  | x | x | x | x | x | x | x | x | x | 
| Eye pain | common, 3.3% - 9.3% |  | x | x | x | x | x | x | x | x | x | x | 
| Skin hyperpigmentation | common |  | x | x |  |  |  |  | x | x | x |  | 
| Punctate keratitis | common |  |  | x | x | x | x | x | x | x | x |  | 
| Vision blurred | postmarketing, common |  | x | x |  |  |  |  | x | x | x | x | 
| Lacrimation | common |  |  | x | x | x | x | x | x | x | x |  | 
| Sensation of foreign body | common, 2.1% - 9.9% |  |  | x | x | x | x | x | x | x | x | x | 
| Visual disturbance | common, 4.6% - 7.7% |  |  | x | x | x | x | x | x | x | x | x | 
| Eyelash darkening | common |  |  |  | x | x | x | x | x | x | x |  | 
| Eye discharge | common, 0.8% - 4.1% |  | x | x | x | x | x | x | x | x | x | x | 
| Erythema of eyelid | common, 0.8% - 3.8% |  | x |  | x | x | x |  | x | x | x | x | 
| Eye irritation | common, 1.2% - 3.5% |  | x | x | x | x | x | x | x | x | x | x | 
| Eyelash discolouration | 0.4% - 5.2% |  |  |  |  |  |  |  |  |  |  | x | 
| Asthenopia | common, 0.4% - 3.1% |  |  | x | x | x | x | x | x | x | x | x | 
| Blepharitis | common, 1.7% - 2.9% |  | x | x | x | x | x | x | x | x | x | x | 
| Lacrimation increased | postmarketing — 1.5% - 2.7% |  | x | x |  |  |  |  | x | x |  | x | 
| Keratitis | 2.3% - 2.5% |  |  |  |  |  |  |  |  |  |  | x | 
| Eyelids pruritus | postmarketing — 0.2% - 4.1% |  | x | x |  |  |  |  | x | x | x | x | 
| Conjunctival oedema | common, 1.2% - 1.9% |  |  | x | x | x | x | x | x | x | x | x | 
| Stinging | 0.8% - 2.1% |  |  |  |  |  |  |  |  |  |  | x | 
| Conjunctivitis allergic | common, 0% - 1.5% |  |  | x | x | x | x | x | x | x | x | x | 
| Asthenia | common, 0.8% - 1.4% |  |  | x | x | x | x | x | x | x | x | x | 
| Cataract | 1.2% - 2.9% |  |  | x | x | x | x | x |  |  |  | x | 
| Corneal erosion | common, 0.8% - 1.2% |  |  |  |  |  |  |  | x | x | x | x | 
| Hypertension | postmarketing, 0.8% - 1.9% |  |  |  |  |  |  | x | x | x | x | x | 
| Blepharospasm | uncommon |  |  |  |  |  |  |  | x | x | x | x | 
| Common cold | uncommon |  |  | x | x | x | x | x | x | x |  |  | 
| Infection | uncommon, 0.4% - 1.3% |  |  | x | x | x | x | x | x | x |  | x | 
| Hirsutism | uncommon, 0% - 1.4% |  |  |  | x | x |  |  | x | x | x | x | 
| Iritis | uncommon |  |  | x | x | x | x | x | x | x | x | x | 
| Retinal haemorrhage | uncommon |  |  |  |  |  |  |  | x | x | x |  | 
| Upper respiratory tract infection | uncommon |  |  | x | x | x | x | x | x | x |  |  | 
| Vertigo | uncommon |  |  |  |  |  |  |  | x | x |  |  | 
| Eyelid retraction | uncommon |  |  |  |  |  |  |  | x | x | x |  | 
| Dizziness | postmarketing, 0.5% - 1.2% |  |  |  |  |  |  | x | x | x | x | x | 
| Depression | 0% - 1% |  |  |  |  |  |  |  |  |  |  | x | 
| Rhinitis | 0% - 1.9% |  |  |  |  |  |  |  |  |  |  | x | 
| Eyelid oedema | postmarketing, uncommon |  | x | x |  |  |  | x | x | x | x | x | 
| Enophthalmos | postmarketing |  |  |  |  |  |  |  | x | x | x |  | 
| Rash | postmarketing |  | x | x |  |  |  |  |  |  |  | x | 
| Eye disorder | postmarketing |  | x |  |  |  |  |  | x | x | x |  | 
| Gastrointestinal disorder | postmarketing |  |  |  |  |  |  |  | x | x | x |  | 
| Nausea | postmarketing |  |  |  |  |  |  | x | x | x | x |  | 
| Nervous system disorder | postmarketing |  |  |  |  |  |  |  | x | x | x |  | 
| Erythema | postmarketing |  |  |  |  |  |  |  | x | x |  |  | 
| Angiopathy | postmarketing |  |  |  |  |  |  |  | x | x | x |  | 
| Burning sensation | postmarketing |  | x | x |  |  |  |  |  |  |  |  | 
| Skin discolouration | postmarketing |  | x | x |  |  |  |  |  |  |  |  | 
| Unspecified disorder of skin and subcutaneous tissue | postmarketing |  | x |  |  |  |  |  | x | x | x |  | 
| Hair growth abnormal | postmarketing |  | x | x |  |  | x | x | x | x |  |  | 
| Eye swelling | postmarketing |  | x | x |  |  |  |  |  |  |  |  | 
| Macular oedema | postmarketing |  |  |  |  |  |  |  | x | x |  |  | 
| Madarosis | postmarketing |  | x | x |  |  |  |  |  |  | x |  | 
| Trichorrhexis | postmarketing |  | x | x |  |  |  |  |  |  |  |  | 
| Iris hyperpigmentation | postmarketing |  | x | x |  |  |  |  |  |  | x |  | 
| Eyelid irritation | postmarketing |  | x | x |  |  |  |  |  |  |  |  | 
| Anxiety |  |  |  |  |  |  |  |  |  |  |  | x | 
| Arthritis |  |  |  |  |  |  |  |  |  |  |  | x | 
| Asthma |  |  |  |  |  |  |  |  |  |  | x |  | 
| Bronchitis |  |  |  |  |  |  |  |  |  |  |  | x | 
| Chalazion |  |  |  |  |  |  |  |  |  |  |  | x | 
| Chest pain |  |  |  |  |  |  |  |  |  |  |  | x | 
| Conjunctival disorder |  |  |  |  |  |  |  |  |  |  | x |  | 
| Conjunctival haemorrhage |  |  |  |  |  |  | x | x |  |  |  |  | 
| Connective tissue disorder |  |  |  |  |  |  |  |  | x | x |  |  | 
| Corneal oedema |  |  |  |  |  |  |  |  |  |  |  | x | 
| Cystitis |  |  |  |  |  |  |  |  |  |  |  | x | 
| Diplopia |  |  |  |  |  |  |  |  |  |  |  | x | 
| Dyspepsia |  |  |  |  |  |  |  |  |  |  |  | x | 
| Dyspnoea |  |  |  |  |  |  |  |  |  |  | x | x | 
| Vitreous floaters |  |  |  |  |  |  |  |  |  |  |  | x | 
| Hordeolum |  |  |  |  |  |  |  |  |  |  |  | x | 
| Hypercholesterolaemia |  |  |  |  |  |  |  |  |  |  |  | x | 
| Hypertrichosis |  |  |  |  |  |  |  |  |  |  | x |  | 
| Inflammation |  |  |  |  | x | x | x | x |  |  |  | x | 
| Cystoid macular oedema |  |  |  |  |  |  |  |  |  |  | x |  | 
| Mediastinal disorder |  |  |  |  |  |  |  |  | x | x | x |  | 
| Nervousness |  |  |  |  |  |  |  |  |  |  |  | x | 
| Palpitations |  |  |  |  |  |  |  |  |  |  |  | x | 
| Pharyngitis |  |  |  |  |  |  |  |  |  |  |  | x | 
| Scotoma |  |  |  |  |  |  |  |  |  |  |  | x | 
| Sinusitis |  |  |  |  |  |  |  |  |  |  |  | x | 
| Uveitis |  |  |  |  |  |  |  |  |  |  | x |  | 
| Dry mouth |  |  |  |  |  |  |  |  |  |  |  | x | 
| Oedema peripheral |  |  |  |  |  |  |  |  |  |  |  | x | 
| Liver function test abnormal |  |  |  |  | x | x | x | x |  |  | x | x | 
| Dry skin |  |  |  |  |  |  |  |  |  |  | x |  | 
| Urine abnormality |  |  |  |  |  |  |  |  |  |  |  | x | 
| Exacerbation of asthma |  |  |  |  |  |  |  |  |  |  | x |  | 
| Cough increased |  |  |  |  |  |  |  |  |  |  |  | x | 
| COPD exacerbation |  |  |  |  |  |  |  |  |  |  | x |  | 
| Eye oedema |  |  |  |  |  |  |  |  |  |  |  | x | 
| Corneal calcification |  |  |  |  |  |  |  |  |  |  | x |  | 
| Erythema periorbital |  |  | x | x |  |  |  | x |  |  | x |  | 
| Insomnia |  |  |  |  |  |  |  |  |  |  |  | x | 
| Conjunctival bleb |  |  |  |  |  |  |  |  |  |  |  | x | 
| Eyelid margin crusting |  |  |  |  |  |  |  |  |  |  | x |  | 
| Instillation site irritation |  |  |  |  |  |  |  |  |  |  | x |  | 
| Eyelid pain |  |  |  |  |  |  |  |  |  |  |  | x | 
| Somnolence |  |  |  |  |  |  |  |  |  |  |  | x | 
	 
 
  Indications
	Information about indications was extracted from the indications and usage sections of the labels.
	
 
	  
	  
		| Side effects: | 25 | 
|---|
		| Source: | Medsafe | 
|---|
		 
	  
	  
		| Side effects: | 37 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 27 | 
|---|
		| Source: | FDA | 
|---|
		 
	  
	  
		| Side effects: | 27 | 
|---|
		| Source: | FDA | 
|---|
		 
	  
	  
		| Side effects: | 28 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 32 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 48 | 
|---|
		| Source: | medicines.org.au | 
|---|
		 
	  
	  
		| Side effects: | 48 | 
|---|
		| Source: | Medsafe | 
|---|
		 
	  
	  
		| Side effects: | 56 | 
|---|
		| Source: | EMA | 
|---|
		 
	  
	  
		| Side effects: | 67 | 
|---|
		| Source: | Health Canada | 
|---|
		 
	  
  
 
  
	Color scheme:
	  
	  standard – alternative
	  
	
	
|  |  | 100% | 
|  |  | 75% | 
|  |  | 50% | 
|  |  | 10% | 
|  |  | frequent (1% to 100%) | 
|  |  | infrequent (0.1% to 1%) | 
|  |  | rare (<0.1%) | 
|  |  | postmarketing | 
|  |  | 0% | 
|  |  | no frequency information | 
|  |  | not found on label |